Product Researcher

5000

Graniman Bio focuses on the research and development of high-throughput gene editing tools to serve new drug development and basic research. The company is committed to creating the most simple and easy-to-use CRISPR gene knockout tool, freeing developers from tedious optimization experiments such as virus packaging, plasmid preparation, Cas9 protein concentration testing, and focusing on biological discovery. Granman high-throughput gene knockout platform has completed 20000 gene knockout verification in human primary cells, more than 80% of the targets have more than 70% knockout efficiency, the company currently has gene knockout automation, high-throughput production platform, reaching 400 + high knockout efficiency KO cell capacity per month.

Graniman Bio focuses on the research and development of high-throughput gene editing tools to serve new drug development and basic research. The company is committed to creating the most simple and easy-to-use CRISPR gene knockout tool, freeing developers from tedious optimization experiments such as virus packaging, plasmid preparation, Cas9 protein concentration testing, and focusing on biological discovery. Granman high-throughput gene knockout platform has completed 20000 gene knockout verification in human primary cells, more than 80% of the targets have more than 70% knockout efficiency, the company currently has gene knockout automation, high-throughput production platform, reaching 400 + high knockout efficiency KO cell capacity per month. Graniman Bio focuses on the research and development of high-throughput gene editing tools to serve new drug development and basic research. The company is committed to creating the most simple and easy-to-use CRISPR gene knockout tool, freeing developers from tedious optimization experiments such as virus packaging, plasmid preparation, Cas9 protein concentration testing, and focusing on biological discovery. Granman high-throughput gene knockout platform has completed 20000 gene knockout verification in human primary cells, more than 80% of the targets have more than 70% knockout efficiency, the company currently has gene knockout automation, high-throughput production platform, reaching 400 + high knockout efficiency KO cell capacity per month.

<Return to Recruitment List